Rincón, Raúl <br/><br/>
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.  [electronic resource] 

 -  Oncotarget  Feb 2015 
 - 4299-314 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.3012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Antibiotics, Antineoplastic--pharmacology<br/>Biomarkers, Tumor--analysis<br/>Blotting, Western<br/>Breast Neoplasms--drug therapy<br/>Doxorubicin--pharmacology<br/>Drug Resistance, Neoplasm--physiology<br/>Enzyme Activation--physiology<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Mice<br/>Mice, Inbred BALB C<br/>Middle Aged<br/>Prognosis<br/>Protein Phosphatase 2--metabolism<br/>Real-Time Polymerase Chain Reaction<br/>Treatment Outcome